Literature DB >> 25596961

Combined heart-kidney transplantation after total artificial heart insertion.

A Ruzza1, L S C Czer2, K A Ihnken1, M Sasevich1, A Trento1, D Ramzy1, F Esmailian1, J Moriguchi3, J Kobashigawa3, F Arabia1.   

Abstract

We present the first single-center report of 2 consecutive cases of combined heart and kidney transplantation after insertion of a total artificial heart (TAH). Both patients had advanced heart failure and developed dialysis-dependent renal failure after implantation of the TAH. The 2 patients underwent successful heart and kidney transplantation, with restoration of normal heart and kidney function. On the basis of this limited experience, we consider TAH a safe and feasible option for bridging carefully selected patients with heart and kidney failure to combined heart and kidney transplantation. Recent FDA approval of the Freedom driver may allow outpatient management at substantial cost savings. The TAH, by virtue of its capability of providing pulsatile flow at 6 to 10 L/min, may be the mechanical circulatory support device most likely to recover patients with marginal renal function and advanced heart failure.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25596961     DOI: 10.1016/j.transproceed.2014.09.106

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  2 in total

1.  Trends and outcomes following total artificial heart as bridge to transplant from the UNOS database.

Authors:  Garrett N Coyan; Lauren V Huckaby; Carlos E Diaz-Castrillon; Alyssa M Miguelino; Arman Kilic
Journal:  J Card Surg       Date:  2022-02-19       Impact factor: 1.620

2.  Combined Heart and Kidney Transplantation: Clinical Experience in 100 Consecutive Patients.

Authors:  Morcos Atef Awad; Lawrence S C Czer; Dominic Emerson; Stanley Jordan; Michele A De Robertis; James Mirocha; Evan Kransdorf; David H Chang; Jignesh Patel; Michelle Kittleson; Danny Ramzy; Joshua S Chung; J Louis Cohen; Fardad Esmailian; Alfredo Trento; Jon A Kobashigawa
Journal:  J Am Heart Assoc       Date:  2019-02-19       Impact factor: 5.501

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.